source
- BioMarin drug acquired in buyout misses goal in rare disease studyTested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.BioPharma Dive · 2mo ago↗ source
- The state of consumer healthOn Thursday, the Health Tech team led a series of conversations at the Financial Times’ US Pharma and Biotech Summit, held in collaboration with Endpoints News. The sessions focused on ...Endpoints · 2mo ago↗ source
- Q&A: Novo research chief Petersen says streamlined R&D speeds discoveryJust as Maziar Mike Doustdar took the helm at Novo Nordisk in the summer of 2025, the company said it would reorganize its R&D activities, merging the teams that focused on early ...Endpoints · 2mo ago